Literature DB >> 10520809

Angiotensin I-converting enzyme and plasminogen activator inhibitor-1 gene variants: risk of mortality and fatal cardiovascular disease in an elderly population-based cohort.

B T Heijmans1, R G Westendorp, D L Knook, C Kluft, P E Slagboom.   

Abstract

OBJECTIVES: We studied the contribution of putative risk genotypes at the angiotensin I-converting enzyme inhibitor (ACE D/D) and plasminogen activator inhibitor-1 (PAI-1 4G/4G) loci to all-cause and cardiovascular mortality in a population-based cohort.
BACKGROUND: The ACE D/D and PAI-1 4G/4G genotypes have been consistently associated with elevated plasma activities of the gene products. Their role in cardiovascular disease, although explored intensively, is still equivocal.
METHODS: The ACE and PAI-1 genotypes were determined in 648 subjects > or =85 years old. In a cross-sectional analysis, the genotype distributions in a subset of 356 elderly subjects who were born in Leiden, The Netherlands, were compared with those in 250 young subjects whose families originated from the same geographic region. In addition, the complete cohort of elderly subjects was followed over 10 years for all-cause and cardiovascular mortality and was stratified according to genotype.
RESULTS: In the cross-sectional analysis, the ACE and PAI-1 genotype distributions were similar in elderly and young subjects. In the prospective follow-up study, however, the age-adjusted risk of fatal ischemic heart disease was increased threefold (95% confidence interval [CI] 1.2 to 7.6) in elderly men carrying the PAI-1 4G/4G genotype. The risk of all-cause mortality was not increased among elderly subjects carrying the PAI-1 4G/4G (relative risk [RR] 0.9, 95% CI 0.7 to 1.1) or the ACE D/D genotype (RR 0.9, 95% CI 0.7 to 1.1), nor did we observe elevated risks of death from all cardiovascular diseases combined. There was no interaction between the genotypes.
CONCLUSIONS: The PAI 4G/4G genotype may be a risk factor for fatal ischemic heart disease in elderly men. The impact of moderately increased ACE and PAI-1 activities associated with the ACE D/D and PAI-1 4G/4G genotypes is too small to affect mortality in the general population.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10520809     DOI: 10.1016/s0735-1097(99)00337-x

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  3 in total

1.  Plasminogen activator inhibitor-1 4G/5G promoter polymorphism and PAI-1 plasma levels in young patients with ischemic stroke.

Authors:  Adriano de Paula Sabino; Daniel Dias Ribeiro; Caroline Pereira Domingueti; Mariana Silva Dos Santos; Telma Gadelha; Luci Maria Santana Dusse; Maria das Graças Carvalho; Ana Paula Fernandes
Journal:  Mol Biol Rep       Date:  2011-03-04       Impact factor: 2.316

2.  Angiotensin I - Converting Enzyme Gene Polymorphism and Activity in Patients with Ischemic Stroke.

Authors:  Sanja Stankovic; Aleksandra Stankovic; Milika Asanin; Zagorka Jovanovic-Markovic; Dragan Alavantic; Nada Majkic-Singh
Journal:  EJIFCC       Date:  2011-01-03

Review 3.  Puzzling role of genetic risk factors in human longevity: "risk alleles" as pro-longevity variants.

Authors:  Svetlana Ukraintseva; Anatoliy Yashin; Konstantin Arbeev; Alexander Kulminski; Igor Akushevich; Deqing Wu; Gaurang Joshi; Kenneth C Land; Eric Stallard
Journal:  Biogerontology       Date:  2015-08-26       Impact factor: 4.277

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.